Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELAD study of liraglutide in mild Alzheimer's disease
2013-000962-13Phase 2Unknown
- Sponsor
- Imperial College London
- Start
- Jun 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Victoza with Placebo (2 arms). Primary endpoint: Change from baseline to 12 months in cognitive z-scores. Status: unknown.
02
Drugs
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2013-000962-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000962-13.